Recombinant Rhesus Macaque ADM2 Protein Pre-coupled Magnetic Beads
Cat.No. : | ADM2-79R-B |
Product Overview : | The Recombnant protein was conjugated to magnetic beads. This ready-to-use, pre-coupled magnetic beads are in uniform particle size and narrow size distribution with large surface area, which is conducive to convenient and fast capture target molecules with high specificity and achieve magnetic separation. This product can be equipped with automation equipment for high-throughput operations. |
- Specification
- Gene Information
- Related Products
- Download
Source : | HEK293 |
Species : | Rhesus Macaque |
Form : | Solution |
Particle size : | ~2 μm |
Beads Surface : | Hydrophilic |
Capacity : | > 200 pmol rabbit IgG/ mg beads |
Applications : | Immunoassay, In vitro diagnostics, cell sorting, Immunoprecipitation/Co-precipitation, Protein/antibody separation and purification. |
Stability : | Stable for at least 6 months from the date of receipt of the product under proper storage and handling conditions. |
Storage : | 2-8℃. Do not to freeze thaw the Beads |
Concentration : | 10mg beads/mL |
Storage Buffer : | PBS buffer |
Gene Name : | ADM2 adrenomedullin 2 [ Macaca mulatta (Rhesus monkey) ] |
Official Symbol : | ADM2 |
Synonyms : | ADM2; ADM2; |
Gene ID : | 720666 |
mRNA Refseq : | NM_001194708 |
Protein Refseq : | NP_001181637 |
UniProt ID : | F7D000 |
Products Types
◆ Recombinant Protein | ||
ADM2-352M | Recombinant Mouse ADM2 Protein, His (Fc)-Avi-tagged | +Inquiry |
ADM2-187R | Recombinant Rat ADM2 Protein, His (Fc)-Avi-tagged | +Inquiry |
ADM2-79R | Recombinant Rhesus Macaque ADM2 Protein, His (Fc)-Avi-tagged | +Inquiry |
ADM2-86H | Recombinant Human ADM2 Protein, His-tagged | +Inquiry |
ADM2-2779H | Recombinant Human ADM2 Protein, His-tagged, OVA Conjugated | +Inquiry |
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Q&As
- Reviews
Q&As (9)
Ask a questionADM2 agonists are still in the experimental stage and are not yet available for clinical use. However, several drug candidates are currently being evaluated in preclinical studies and clinical trials, and may eventually be developed as new therapies for the treatment of pain and other disorders.
ADM2 proteins have been implicated in the regulation of pain perception. ADM2 has been shown to decrease pain sensitivity in animal models of chronic pain, and ADM2 agonists may be potential treatments for chronic pain conditions.
There is some evidence to suggest that ADM2 agonists may have therapeutic potential in the treatment of anxiety and depression. However, more research is needed to determine the safety and efficacy of ADM2 agonists for these conditions.
ADM2 proteins are being studied for potential therapies for cardiovascular disease because of their vasodilatory and cardioprotective effects. ADM2 agonists, which mimic the activity of ADM2, are being developed as potential treatments for hypertension, heart failure, and other cardiovascular disorders.
ADM2 proteins can interact with the immune system in several ways. ADM2 has been shown to modulate the activity of immune cells, including T cells, B cells, and macrophages. ADM2 can promote the production of anti-inflammatory cytokines and inhibit the production of pro-inflammatory cytokines.
Unlike opioids, ADM2 agonists do not bind to opioid receptors and therefore do not produce the same side effects associated with opioid use, such as addiction and respiratory depression. ADM2 agonists may offer a safer alternative for the management of chronic pain.
ADM2 agonists could have a significant impact on the opioid epidemic by providing a safer alternative for pain management. Unlike opioids, ADM2 agonists do not produce the same addictive effects, respiratory depression, or risk of overdose. By providing a non-addictive alternative for pain management, ADM2 agonists could help reduce the number of people who become addicted to opioids. Additionally, ADM2 agonists could potentially be used to help people who are already addicted to opioids to manage their pain without increasing their risk of overdose or other adverse effects.
There have been no reported side effects associated with ADM2 agonists in clinical trials to date. However, as with any new drug, long-term safety and efficacy will need to be established in larger clinical studies.
ADM2 proteins have been studied as a potential biomarker for sepsis, a life-threatening condition that occurs when the body's immune response to infection becomes dysregulated. ADM2 levels have been shown to be elevated in patients with sepsis, and may be useful for diagnosing and monitoring the condition.
Customer Reviews (4)
Write a reviewThe manufacturer's attention to detail in the protein's production process is evident, and I am confident that this product will provide me with accurate and dependable data.
the unparalleled technical support provided by the manufacturer has given me the confidence that any challenges I may encounter can be swiftly and effectively resolved.
the purity and consistency of the ADM2 protein have exceeded my expectations, ensuring that my experiments will yield reliable and reproducible results.
After conducting extensive research, I have determined that ADM2 protein is of exceptional quality and will undoubtedly meet all of my experimental requirements.
Ask a Question for All ADM2 Products
Required fields are marked with *
My Review for All ADM2 Products
Required fields are marked with *
Inquiry Basket